Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 50 clinical trials
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

this study is to assess the tolerability and efficacy of combining Durvalumab (MEDI4736), Tremelimumab and SBRT in controlling cancer progression. SBRT will be administered to patients while they are

locoregional recurrence
durvalumab
metastasis
serum pregnancy test
measurable disease
  • 21 views
  • 27 Feb, 2022
  • 3 locations
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus (RICE)

A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced

oophorectomy
tremelimumab
follicle stimulating hormone
tubal ligation
medi4736
  • 0 views
  • 23 Mar, 2022
  • 2 locations
Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

CTLA-4 Inhibitor Tremelimumab in patients with intrahepatic Biliary Tract Cancer

hepatitis b surface antigen
durvalumab
biliary tract cancer
metastasis
progressive disease
  • 1 views
  • 06 May, 2022
  • 3 locations
Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design

A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design

  • 0 views
  • 05 Jun, 2022
  • 1 location
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

This is a phase II randomized, open label study of durvalumab with/ without tremelimumab as neoadjuvant therapy and durvalumab maintenance after SoC RTx with/without cisplatin as post-surgical

  • 0 views
  • 02 May, 2021
  • 1 location
--- SMARTEST Trial---

sub-ablative radiation alone (Arm B) before surgery as well as the safety and efficacy of consolidation tremelimumab-durvalumab for eligible patients after surgery in both arms.

  • 0 views
  • 07 Jun, 2022
  • 1 location
A Phase II Study of Durvalumab

durvalumab (+/- tremelimumab)

metastasis
pemetrexed
pd-l1
liver metastasis
measurable disease
  • 1 views
  • 21 Jul, 2022
  • 7 locations
Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy (OPTIMUM)

therapy for advanced biliary tract cancer without progression to first-line gemcitabine plus cisplatin chemotherapy. Durvalumab with/without tremelimumab, anti-CTLA4 inhibitor, showed encouraging

  • 0 views
  • 19 Apr, 2022
  • 1 location
Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING) (GOING)

failure. Recently, the combination of tremelimumab and durvalumab improved OS in comparison to sorafenib; in addition, durvalumab monotherapy was not inferior to sorafenib. The aim of this study

metastasis
liver disease
RET
TACE
measurable disease
  • 0 views
  • 24 May, 2022
  • 5 locations
Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

This is an interventional, prospective multicenter, open-label, phase II study in patients after curative surgery for BTC in a classic adjuvant situation, consisting of a two arm feasibility pilot part with a randomized pick-the-winner design and an option to proceed into a randomized phase 2/3 trial in order to compare …

  • 0 views
  • 11 Jul, 2022
  • 1 location